Format

Send to

Choose Destination
Oncologist. 2015 Feb;20(2):224-6. doi: 10.1634/theoncologist.2014-0309. Epub 2015 Jan 7.

Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Author information

1
Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California, USA.
2
Jonsson Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA.
PMID:
25568147
PMCID:
PMC4319629
DOI:
10.1634/theoncologist.2014-0309
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center